UPDATE: Nektar Highlights Bayer Announced Phase 3 Amikacin Inhale Did Not Meet Primary Or Key Secondary Endpoints; Co. Does Not Expect Bayer To Move Forward With Program, Does Not Expect Any Further Performance Obligations
Paul Quintaro